2701680-77-3

2701680-77-3 structure

Name: Tofacitinib-d3 citrate
Chemical Name: Tofacitinib-d3 citrate
CAS Number: 2701680-77-3
Molecular Formula: C₂₂H₂₅D₃N₆O₈
Molecular Weight: 507.51
Catalog: Signaling Pathways Anti-infection Bacterial
Create Date: 2022-07-29 18:46:41
Modify Date: 2024-01-02 14:24:54
Tofacitinib-d3 (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

Name	Tofacitinib-d3 citrate

Description	Tofacitinib-d3 (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Signaling Pathways >> Anti-infection >> Influenza Virus Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK Research Areas >> Infection Signaling Pathways >> Anti-infection >> Fungal Research Areas >> Inflammation/Immunology Signaling Pathways >> Anti-infection >> Bacterial
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Jiang JK, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem. 2008 Dec 25;51(24):8012-8. [3]. Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193(1):48-55. [4]. LaBranche TP, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012 Nov;64(11):3531-42. [5]. Yagi K, et al. Pharmacological inhibition of JAK3 enhances the antitumor activity of STI571 in human chronic myeloid leukemia. Eur J Pharmacol. 2018 Apr 15;825:28-33.

Molecular Formula	C₂₂H₂₅D₃N₆O₈
Molecular Weight	507.51

2701680-77-3	540737-29-9
1640971-60-3	1092578-44-3
1092578-43-2	477600-76-3
2315287-12-6	2268720-86-9
2459302-86-2	477600-75-2